Every Form 4 that United Therapeutics Corp (UTHR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow UTHR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full UTHR filings page.
United Therapeutics Corp director Louis W. Sullivan received an annual non-employee director stock option award covering 2,380 shares of common stock at an exercise price of $527.07 per share. The options vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027, and expire on July 22, 2033. After this filing, he holds 2,983 common shares directly and 1,457 shares indirectly through a trust over which he has sole investment and voting power; totals were updated to correct a prior underreporting of 590 trust shares.
United Therapeutics Corp director Christopher Causey received an annual non-employee director stock option award covering 2,380 shares of common stock at a $527.07 exercise price, expiring July 22, 2033. The options become fully vested on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. Following this grant, he directly holds 4,190 common shares and options on 2,380 shares.
United Therapeutics director Christopher Patusky received a grant of 2,380 stock options on July 22, 2026, with an exercise price of $527.07 per share, expiring July 22, 2033. This annual non-employee director award becomes fully vested on the earlier of the one-year anniversary of the grant date or the date of the next Annual Meeting of Shareholders, which is anticipated to be June 25, 2027. Following the grant, he directly holds 2,380 options under this award and 2,410 shares of common stock.
Giltner Richard reported acquisition or exercise transactions in this Form 4 filing.
United Therapeutics Corp director Richard Giltner received an annual non-employee director award of 760 restricted stock units, each representing one share of common stock upon vesting.
The RSUs vest on the earlier of the one-year anniversary of the grant or the next Annual Meeting of Shareholders, anticipated on June 25, 2027. After this award he holds 760 RSUs and 21,884 common shares directly.
United Therapeutics Corp director Ray Kurzweil received annual equity awards consisting of 380 restricted stock units and 1,190 stock options on July 22, 2026. The awards vest in full on the earlier of the one-year anniversary of the grant or the next Annual Meeting, anticipated on June 25, 2027. The options carry an exercise price of $527.07 per share and expire on July 22, 2033. Following these awards, he directly holds 13,320 shares of United Therapeutics common stock. The restricted stock units have no expiration date and each converts into one share upon vesting.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 22, 2026 and sold 9,500 shares in multiple trades at weighted-average prices reported from $524.27 to $539.47 per share. These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following the exercise, family trusts held 293,910 stock options, while Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly through a spouse.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 on July 21, 2026, acquiring 9,500 common shares, then sold 9,500 shares in multiple open-market trades at weighted-average prices between $523.81 and $537.13. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following this option exercise, a family trust holds 303,410 stock options, while Rothblatt also directly owns 40,513 common shares and has additional indirect holdings including 166 shares held by a spouse.
United Therapeutics Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 20, 2026, then sold an equal 9,500 shares in multiple open-market trades. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which permits the exercise of up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026. After this exercise, a family trust continues to hold 312,910 stock options, while Rothblatt also holds 40,513 common shares directly and 166 shares indirectly via her spouse.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported an exercise-and-sale sequence involving company stock on July 17, 2026. Family trusts associated with the reporting person exercised 9,500 stock options at $135.42 per share and sold 9,500 common shares across 11 transactions at weighted-average prices ranging from $528.39 to $542.49.
All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026. After the reported trades, family trusts and related indirect holdings reported 324,443 common shares and 322,410 stock options remaining.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on July 16, 2026, and on the same date sold 9,500 shares of common stock in multiple trades, including a tranche at a weighted average price of $530.1449 per share. These option exercises and sales were carried out by a family trust under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. After these transactions, that family trust held 324,443 shares of United Therapeutics common stock, while Rothblatt also reported 40,513 shares held directly and 331,910 stock options held in a family trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts and personal accounts, exercised stock options for 9,500 shares at $135.4200 per share and sold 9,500 shares of common stock in multiple open-market trades at prices between $520.9158 and $534.2733 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows for the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or terminates by December 31, 2026.
United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share and sold 8,300 shares in multiple open-market trades at prices between $527.5950 and $536.8526. These trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, and Mahon continues to hold 80,740 stock options afterward.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.4200 per share and on the same date sold 9,500 common shares in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 common shares directly and also maintains additional common stock and stock options through family trusts and her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $135.4200 per share and sold 9,500 shares in open-market trades on July 13, 2026, with reported prices including $542.8000 and $533.7022 per share. The exercise and sales were carried out under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. After these transactions, Rothblatt holds 40,513 shares directly, plus additional indirect common stock and stock option positions in family trusts and a spouse account, including stock options over 349,192 underlying shares at a $135.4200 exercise price expiring March 15, 2027.
UNITED THERAPEUTICS Corp director Richard Giltner reported the vesting of equity compensation and related share issuance. On July 9, 2026, 1,310 restricted stock units vested and converted on a one-for-one basis into 1,310 shares of common stock. Following this RSU vesting and conversion, Giltner holds 21,884 shares of common stock directly. The restricted stock units had no expiration date and were converted at a price of $0.00 per unit, reflecting non-cash equity compensation rather than an open-market purchase or sale.
UNITED THERAPEUTICS Corp director Ray Kurzweil reported the vesting and exercise of 650 restricted stock units into an equal number of shares of common stock on July 9, 2026. The RSUs converted on a one-for-one basis with no exercise price. Following the transaction, Kurzweil holds 13,320 shares of common stock directly.
UNITED THERAPEUTICS Corp director Nilda Mesa reported the vesting and conversion of equity awards. On July 9, 2026, 650 restricted stock units vested and were converted on a one-for-one basis into 650 shares of common stock. Following this compensation-related transaction, Mesa directly holds 5,678 shares of common stock.
UNITED THERAPEUTICS Corp director Judy D. Olian reported the vesting of equity awards. On July 9, 2026, 1,310 Restricted Stock Units vested and converted on a one-for-one basis into 1,310 shares of common stock at an exercise price of $0.00 per share. Following this conversion, Olian holds 5,555 shares of common stock directly, and the reported Restricted Stock Unit position is reduced to zero. The transactions reflect compensation-related vesting, not an open‑market purchase or sale.
UNITED THERAPEUTICS Corp director Christopher Patusky reported a compensation-related equity event. On July 9, 2026, 650 Restricted Stock Units vested and converted on a one-for-one basis into 650 shares of common stock at a stated price of $0.00 per share. Following this vesting, he held 2,140 shares of common stock directly, in addition to 1,100 shares held indirectly by trust. The RSU award involved in this transaction was fully converted, with no remaining units from that grant.
UNITED THERAPEUTICS Corp director Louis W. Sullivan reported the vesting of 650 restricted stock units on July 9, 2026, which converted on a one-for-one basis into 650 shares of common stock. Following the transaction, he holds 2,983 common shares directly and 867 common shares indirectly through a trust over which he has sole investment and voting power.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported a series of transactions in Common Stock on July 10, 2026. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of Common Stock in multiple open-market trades at prices reported between $540.37 and $553.47 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, she holds 40,513 shares of Common Stock directly, plus additional indirect holdings in family trusts and stock options on 349,192 shares held indirectly through a family trust.
UNITED THERAPEUTICS Corp director Jan Malcolm received 650 shares of common stock on July 9, 2026 upon vesting of restricted stock units that converted one-for-one into common shares. On July 10, 2026, Malcolm executed an open-market sale of 325 common shares at $550.59 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, Malcolm directly holds 450 common shares.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in common stock on July 9, 2026. She exercised 9,500 stock options at $135.42 per share and sold the resulting 9,500 shares in multiple open-market trades at weighted average prices around $548–$556, all pursuant to a pre-arranged Rule 10b5-1 trading plan. After these trades, she held 40,513 shares directly, along with additional indirect holdings through family trusts and stock options on 349,192 shares held in a family trust, as well as a plan that may cover the exercise of up to 1,734,410 stock options expiring on March 15, 2027.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options and sold shares in a planned transaction. On 2026-07-08, she exercised options to acquire 9,500 shares of common stock at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades at weighted-average prices in the mid-$550 range. The filing states these option exercises and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 shares of common stock directly and continues to have additional indirect holdings through family trusts and her spouse, as well as stock options held indirectly on 349,192 underlying shares expiring on March 15, 2027.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in the company’s common stock. On July 7, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the mid-$550s to low-$560s.
A footnote states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Following the transactions, Rothblatt directly holds 40,513 common shares and has additional indirect holdings through family trusts and a spouse, as well as stock options on 349,192 underlying shares held indirectly via a family trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. She exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 common shares in open-market trades around $548–$554 per share under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
Following these transactions, she directly holds 40,513 common shares and also has substantial indirect interests through family trusts, including stock options on 349,192 underlying shares at an exercise price of $135.42 expiring on March 15, 2027.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported a mix of option exercises and share sales in company stock. She exercised 9,500 stock options for common shares at an exercise price of $135.42 per share and sold 9,500 common shares in multiple open-market transactions at weighted average prices generally between about $547.45 and $558.18. Following these transactions, she directly held 40,513 shares of common stock. The filing states that the option exercise and resulting share sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which contemplates the potential exercise of up to 1,734,410 stock options expiring on March 15, 2027, and is scheduled to continue until the earlier of that full exercise or December 31, 2026. In addition to direct holdings, Rothblatt has indirect ownership interests through family trusts and a spouse account, and retains stock options held in a family trust covering 349,192 underlying common shares at an exercise price of $135.42 per share expiring on March 15, 2027.
UNITED THERAPEUTICS Corp executive Paul A. Mahon exercised 8,300 stock options and sold 8,300 common shares in pre-planned trades. On the transactions date, he exercised options at a strike price of $146.03 per share and sold the resulting shares in multiple open-market transactions at weighted average prices generally around the mid-$500s per share. The trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, indicating they were scheduled in advance. Following these transactions, Mahon directly owns 45,172 shares of UNITED THERAPEUTICS common stock.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported option exercises and share sales in UTHR stock. On July 1, 2026, she exercised 9,500 stock options at $135.42 per share and received the same number of common shares.
Those 9,500 shares were then sold in a series of open-market transactions at weighted-average prices generally around the mid-$540s per share, with individual trades executed within price ranges from $537.26 to $549.65. Following these transactions, she held 40,513 common shares directly, along with additional indirect holdings through family trusts and her spouse.
The filing notes that this exercise and sale activity was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026, and a family trust continues to hold 349,192 stock options with a $135.42 exercise price.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. On June 30, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share, acquiring the same number of common shares.
The filing shows open‑market sales of 9,500 common shares that day in multiple trades at weighted average prices generally between about $535.93 and $549.44. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until up to 1,734,410 stock options are exercised or until December 31, 2026, whichever occurs first.
After the reported transactions, Rothblatt directly holds 40,513 common shares. She also has additional indirect holdings of common stock and stock options through various family trusts and her spouse’s account, as described in the filing’s ownership footnotes.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $135.42 per share, then sold 9,500 shares in multiple open‑market transactions at prices reported between $539.9783 and $548.9605 per share. These transactions were carried out under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following the trades, Rothblatt directly holds 40,513 shares of common stock and continues to have substantial indirect holdings through family trusts, as well as stock options held indirectly covering 349,192 underlying shares that expire on March 15, 2027.
United Therapeutics chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold 9,500 shares of common stock of United Therapeutics on June 26, 2026. The options carried a $135.42 exercise price and were exercised and sold under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025.
The Form 4 shows multiple open-market sale transactions at prices reported around the low to mid $540s to $550s per share. Following these transactions, Rothblatt held 49,373 common shares directly, along with additional indirect holdings through family trusts and her spouse.
The filing also reports a large remaining stock option position held indirectly via a family trust, covering 349,192 underlying shares at a $135.42 exercise price and expiring on March 15, 2027. The footnotes emphasize that these transactions are part of a continuing 10b5-1 plan that may run until the earlier of exercising 1,734,410 options or December 31, 2026.
United Therapeutics Corp Chairperson and CEO Martine Rothblatt reported option exercises and share sales in United Therapeutics common stock. She exercised stock options covering 9,500 shares at an exercise price of $135.42 per share and sold 9,500 shares in multiple open-market trades.
According to the footnotes, these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. The reported sales were executed in multiple trades at weighted average prices between $543.12 and $555.31 per share.
In addition to direct holdings, various family trusts and a spouse account hold United Therapeutics common stock and stock options, including a family trust stock option position tied to 349,192 underlying shares at a $135.42 exercise price expiring on March 15, 2027.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported a pre-planned option exercise and share sales. On June 24, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $135.4200 per share and sold 9,500 shares in multiple open-market transactions.
The sales, coded "S," occurred at weighted-average prices between roughly $545.46 and $553.48, as detailed in the footnotes. A footnote states these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. Separate entries show additional indirect holdings and stock options held through family trusts and by a spouse.
United Therapeutics Chairperson and CEO Martine Rothblatt reported exercising stock options and selling shares of common stock in a planned transaction. On June 23, 2026, she exercised 9,500 stock options at an exercise price of $135.42 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices around $540–$546 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027, or December 31, 2026. Following the transactions, Rothblatt holds 40,513 shares of common stock directly, additional indirect common stock positions through various family trusts and a spouse account, and stock options on 349,192 underlying shares held indirectly through a family trust.
United Therapeutics Corp Chairperson and CEO Martine A. Rothblatt reported option exercises and related share sales in a Form 4. On June 22, 2026, she exercised stock options to acquire 9,500 shares of common stock at exercise prices of $146.03 and $135.42 per share, then sold 9,500 shares in multiple open-market transactions at prices generally around the mid‑$530s per share, all under a pre-arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she directly holds 49,781 shares of common stock and has an indirect stock option position covering 349,192 underlying shares expiring on March 15, 2027. Additional common shares and options are held indirectly through various family trusts and by her spouse as described in the filing.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options for 8,750 shares of common stock at an exercise price of $146.03 per share and sold 8,750 shares in open‑market transactions on June 22, 2026. The sales were executed at weighted average prices around the mid‑$530s to low‑$540s per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025. Following these transactions, he directly holds 18,876 shares of UNITED THERAPEUTICS common stock.
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $146.03 per share and sold 10,000 shares in multiple open-market trades at prices between $533.25 and $549.17, all pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025. Following these transactions, he directly owned 18,876 shares of common stock and held 8,750 stock options.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt exercised stock options for 9,500 shares of common stock at an exercise price of $146.03 per share, then sold the same 9,500 shares in multiple open-market transactions on June 18, 2026.
The reported sales included trades such as 2,793 shares at $539.62 per share and 160 shares at $552.72 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which covers up to 1,734,410 stock options expiring on March 15, 2027 or runs until December 31, 2026, whichever comes first.
After these transactions, Rothblatt holds 49,533 shares of common stock directly, along with additional indirect holdings through various family trusts and her spouse.
United Therapeutics EVP & General Counsel Paul A. Mahon exercised and sold company stock in a planned transaction. On June 18, 2026, he exercised 8,300 stock options at an exercise price of $146.03 per share and sold the resulting 8,300 common shares in multiple open-market trades under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025. The sales occurred at weighted-average prices generally in the mid-$530s to mid-$550s per share, as detailed in the trade price ranges.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. On June 17, 2026, she exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares of common stock in multiple open-market trades at weighted average prices in the $548–$556 per share range.
According to a footnote, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which may continue until the earlier of exercising up to 1,734,410 stock options expiring on March 15, 2027 or December 31, 2026. The filing also lists additional indirect holdings in United Therapeutics common stock through various family trusts and the reporting person’s spouse.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 16, 2026, she exercised 9,500 stock options at $146.03 per share and acquired the same number of common shares.
Those 9,500 shares were then sold in multiple open-market trades at prices between $545.18 and $554.63 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these trades, she held 40,513 shares of common stock directly, plus additional indirect holdings through various family trusts and a small position of 166 shares held by her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting 9,500 shares of common stock. The options were exercised at an exercise price of $146.03 per share, and the shares were sold in multiple open-market transactions at prices generally in the mid-$540s per share.
According to the filing, these transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The plan continues until the earlier of the exercise of 1,734,410 stock options, all expiring on March 15, 2027, or December 31, 2026. The filing also reports additional indirect holdings in family trusts and by the CEO’s spouse.
United Therapeutics CFO and Treasurer James Edgemond reported a combination of option exercise and share sales. On June 15, 2026, he exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share and converted those options into stock.
On the same date, he sold 10,000 shares of United Therapeutics common stock in multiple open-market transactions, at weighted average prices generally in the low-to-mid $500s per share, as detailed by price ranges in the footnotes. After these transactions, he directly owned 18,876 shares of common stock. The filing states that the option exercise and subsequent sales were made under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025.
United Therapeutics Chairperson & CEO Martine Rothblatt exercised 9,500 stock options at $146.03 per share on June 12, 2026 and sold the resulting 9,500 common shares in multiple trades at weighted prices between $536.82 and $546.11, under a Rule 10b5-1 trading plan adopted November 7, 2025. After these transactions, she holds 40,513 shares directly and 628,049 shares indirectly through family trusts.
UNITED THERAPEUTICS Corp CFO and Treasurer James Edgemond exercised stock options to acquire 10,000 shares of common stock at an exercise price of $117.76 per share, then sold 10,000 shares in multiple open-market trades on the same day under a Rule 10b5-1 trading plan. Following these transactions, he holds 18,876 shares of common stock directly.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On June 11, 2026, she exercised 9,500 stock options at an exercise price of $146.03 per share, acquiring the same number of common shares.
That day, she sold 9,500 common shares in multiple open‑market trades at weighted average prices around $542–$552 per share pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025. Following these transactions, she holds 49,931 common shares directly, with additional shares held indirectly through family trusts and by her spouse.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported option-related trades in company common stock. She exercised 9,500 stock options at an exercise price of $146.03 per share and related open-market sales covered the same number of shares, resulting in a net sale of 9,500 shares according to the filing summary.
The transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and 59,910 stock options, and also has additional indirect holdings through various family trusts and a spouse account.
United Therapeutics Corp Chairperson & CEO Martine Rothblatt reported an option exercise and related share sales. On June 9, 2026, she exercised 9,500 stock options for common stock at an exercise price of $146.03 per share, then sold 9,500 common shares in a series of open‑market transactions at weighted average prices around $545–$553 per share.
The filing notes these transactions were carried out under a pre‑arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of exercising 1,734,410 stock options that expire on March 15, 2027 or December 31, 2026. After these trades, the report shows 50,013 common shares held directly, along with additional indirect holdings through various family trusts and by a spouse, and 69,410 stock options remaining from the reported option grant.
United Therapeutics Corp CFO and Treasurer James Edgemond reported an options exercise and related share sales in company common stock. On June 8, 2026, he exercised 10,000 stock options at an exercise price of $117.76 per share to acquire 10,000 shares.
That same day, he sold 10,000 common shares in a series of open‑market transactions at weighted average prices ranging from the mid‑$540s to low‑$550s per share. According to the filing, these trades were made under a pre‑arranged Rule 10b5‑1 trading plan entered into on October 31, 2025.
Following these transactions, Edgemond directly holds 18,876 shares of United Therapeutics common stock, and the filing shows no remaining derivative (stock option) position tied to this grant.